The DOI matches its Crossref record.
Remission Rates in Patients With Anxiety Disorders Treated With Paroxetine
Abstract
BACKGROUND: Approximately 50% to 60% of patients with depression and/or anxiety respond to treatment, but only a minority achieve remission. The continued presence of subsyndromal symptoms in treated depressed (and probably anxious) patients leads to higher relapse rates and increased utilization of health care resources. It is proposed that remission is the appropriate target in the treatment of both depression and the anxiety disorders. AIMS: Rigorous criteria for remission have been proposed for the anxiety disorders and are currently being applied in clinical studies. Using these criteria, data from the paroxetine clinical study database were retrospectively analyzed to determine remission rates following paroxetine treatment across a range of anxiety disorders in the largest analysis of remission data in the anxiety disorders to date. METHOD: These analyses included data from 16 short-term and 6 long-term, randomized, placebo-controlled studies in panic disorder, social anxiety disorder, obsessive-compulsive disorder, posttraumatic stress disorder (short term only), and generalized anxiety disorder (DSM-III-R or DSM-IV). Separate analyses were performed for each disorder, with short- and long-term data analyzed separately. RESULTS: In general, across the range of anxiety disorders studied, in both short- and long-term studies, remission rates were higher for paroxetine compared with placebo, using disorder-specific, global, and functional remission criteria both individually and combined. Remission occurred in a moderate proportion of paroxetine-treated patients after only 8 to 12 weeks of treatment, and longer-term therapy led to even higher remission rates. CONCLUSION: Paroxetine has demonstrated efficacy in treating patients to remission across the range of anxiety disorders studied. Our findings strongly suggest that continuing treatment with paroxetine (and probably other SSRI antidepressants) for 2 to 12 months increases the proportion of patients achieving clinical remission.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These are now drug treatments of documented efficacy for pediatric generalized anxiety disorder, separation anxiety, social anxiety and panic disorder (23,24).”
From Pediatric psychopharmacology: Too much or too little? (2013) · cites this paper as [24]
In the citing paper
“The acceptance of medication use in child psychiatry was based on the results of double-blind, placebo-controlled trials documenting the efficacy of drug treatments for attention-deficit/hyperactivity disorder, enuresis, depression, anxiety disorders, obsessive-compulsive disorder and psychoses.”
From Pediatric psychopharmacology: Too much or too little? (2013) · cites this paper as [24]
Citations
Cited by
Hakamata, Y., Lissek, S., Bar-Haim, Y., Britton, J. C., Fox, N. A., Leibenluft, E., Ernst, M., & Pine, D. S. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.07.021 · Cited by 869
Cannabidiol as a Potential Treatment for Anxiety Disorders
Blessing, E. M., Steenkamp, M. M., Manzanares, J., & Marmar, C. R. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0387-1 · Cited by 695
Research review: attention bias modification (ABM): a novel treatment for anxiety disorders
Bar‐Haim, Y. (2010) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2010.02251.x · Cited by 556
Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: A systematic review
Berger, W., Mendlowicz, M. V., Marques-Portella, C., Kinrys, G., Fontenelle, L. F., Marmar, C. R., & Figueira, I. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.12.004 · Cited by 347
Burn Rehabilitation: State of the Science
Esselman, P. C., Thombs, B. D., Magyar-Russell, G., & Fauerbach, J. A. (2006) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/01.phm.0000202095.51037.a3 · Cited by 307
Metadata
- Authors
- Ballenger, J. C.
- Affiliations
- Medical University of South Carolina (US)
- Corresponding author
- Ballenger, James C.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2004-12-15
- Volume
- 65
- Issue
- 12
- Pages
- 1696-1707
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2053214446
- Cited by
- 82
- References
- 0
- Citations by year
- 2025: 4 · 2024: 4 · 2022: 3 · 2021: 3 · 2020: 3 · 2019: 2 · 2017: 1 · 2016: 2 · 2015: 3 · 2014: 2 · 2013: 4 · 2012: 1
- FWCI
- 13.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- paroxetine, remission rate, anxiety disorders, selective serotonin reuptake inhibitors, panic disorder, social anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder, generalized anxiety disorder, functional remission, long-term treatment, relapse
- MeSH terms
- Adolescent, Adult, Aged, Anxiety Disorders, Female, Humans, Longitudinal Studies, Male, Middle Aged, Obsessive-Compulsive Disorder, Phobic Disorders, Placebos, Psychiatric Status Rating Scales, Retrospective Studies, Stress Disorders, Post-Traumatic, Randomized Controlled Trials as Topic, Panic Disorder, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Paroxetine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Remission Rates in Patients With Anxiety Disorders Treated With Paroxetine. https://app.cochat.ai/papers/10.4088/jcp.v65n1216
- The paper
- Ballenger, J. C. (2004). Remission Rates in Patients With Anxiety Disorders Treated With Paroxetine. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v65n1216
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.